Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Analyst Ratings
Strong Buy
22 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NBIX Stock 12 Month Forecast
Average Price Target
$165.83
▲(25.99% Upside)
| Highest Price Target$200.00 | Average Price Target$165.83 | Lowest Price Target$124.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$160
Buy
21.56%
Upside
Reiterated
08/14/25
We recently hosted a fireside chat with NBIX's CEO at our 2025 Boston, MA. Recall NBIX has two products on the market currently, i.e., Ingrezza (valbenazine for tardive dyskinesia/TD, Huntington's chorea) and Crenessity (crinecerfont for classic congenital adrenal hyperplasia/cCAH). The company also has a robust pipeline, which it plans to showcase at an R&D Day on 12/16.
TR | OpenAI - 4o
$139→$145
Buy
10.17%
Upside
Reiterated
08/13/25
BMO Capital
$124
Hold
-5.79%
Downside
Reiterated
08/04/25
Evercore ISI
$190→$200
Buy
51.95%
Upside
Reiterated
07/31/25
H.C. Wainwright
$168
Buy
27.64%
Upside
Reiterated
07/31/25
William Blair
―
Buy
―
Reiterated
07/31/25
Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy RatingWe see potential investor concern surrounding Ingrezza’s sales outlook, particularly given its narrowing of 2025 sales guidance below its original upper-bound set earlier this year (see below). This is largely due to declining net price assumptions with heavier Part D contracting, but the upside here is that volume has increased with record number patient new starts on therapy being reported. Thus, the debate will now become if increased volumes, particularly in 2026, can overcome pricing pressures as Ingrezza looks to compete against Austedo, currently under the CMS Part D price negotiation procedure within the IRA. Crenessity revenue for the second quarter of $53.2 million significantly beat our estimate of $16.8 million as well as the consensus estimate of $24.0 million.
Guggenheim
$165→$175
Buy
32.96%
Upside
Reiterated
07/31/25
Leerink Partners
$160
Buy
21.56%
Upside
Reiterated
07/31/25
Truist Financial
$163→$165
Buy
25.36%
Upside
Reiterated
07/31/25
Needham
$139→$161
Buy
22.32%
Upside
Reiterated
07/31/25
Wedbush
$137→$141
Buy
7.13%
Upside
Reiterated
07/31/25
Stifel Nicolaus
$166→$174
Buy
32.20%
Upside
Reiterated
07/31/25
TD Cowen
$165→$170
Buy
29.16%
Upside
Reiterated
07/31/25
Oppenheimer
$192
Buy
45.87%
Upside
Reiterated
07/31/25
Morgan Stanley
$150→$158
Buy
20.04%
Upside
Reiterated
07/31/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$160
Buy
21.56%
Upside
Reiterated
08/14/25
We recently hosted a fireside chat with NBIX's CEO at our 2025 Boston, MA. Recall NBIX has two products on the market currently, i.e., Ingrezza (valbenazine for tardive dyskinesia/TD, Huntington's chorea) and Crenessity (crinecerfont for classic congenital adrenal hyperplasia/cCAH). The company also has a robust pipeline, which it plans to showcase at an R&D Day on 12/16.
TR | OpenAI - 4o
$139→$145
Buy
10.17%
Upside
Reiterated
08/13/25
BMO Capital
$124
Hold
-5.79%
Downside
Reiterated
08/04/25
Evercore ISI
$190→$200
Buy
51.95%
Upside
Reiterated
07/31/25
H.C. Wainwright
$168
Buy
27.64%
Upside
Reiterated
07/31/25
William Blair
―
Buy
―
Reiterated
07/31/25
Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy RatingWe see potential investor concern surrounding Ingrezza’s sales outlook, particularly given its narrowing of 2025 sales guidance below its original upper-bound set earlier this year (see below). This is largely due to declining net price assumptions with heavier Part D contracting, but the upside here is that volume has increased with record number patient new starts on therapy being reported. Thus, the debate will now become if increased volumes, particularly in 2026, can overcome pricing pressures as Ingrezza looks to compete against Austedo, currently under the CMS Part D price negotiation procedure within the IRA. Crenessity revenue for the second quarter of $53.2 million significantly beat our estimate of $16.8 million as well as the consensus estimate of $24.0 million.
Guggenheim
$165→$175
Buy
32.96%
Upside
Reiterated
07/31/25
Leerink Partners
$160
Buy
21.56%
Upside
Reiterated
07/31/25
Truist Financial
$163→$165
Buy
25.36%
Upside
Reiterated
07/31/25
Needham
$139→$161
Buy
22.32%
Upside
Reiterated
07/31/25
Wedbush
$137→$141
Buy
7.13%
Upside
Reiterated
07/31/25
Stifel Nicolaus
$166→$174
Buy
32.20%
Upside
Reiterated
07/31/25
TD Cowen
$165→$170
Buy
29.16%
Upside
Reiterated
07/31/25
Oppenheimer
$192
Buy
45.87%
Upside
Reiterated
07/31/25
Morgan Stanley
$150→$158
Buy
20.04%
Upside
Reiterated
07/31/25
Best Analysts Covering Neurocrine
1 Month
xxx
Success Rate
14/24 ratings generated profit
Average Return
+0.46%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +0.46% per trade.
3 Months
xxx
Success Rate
18/28 ratings generated profit
Average Return
+3.50%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +3.50% per trade.
1 Year
Success Rate
18/28 ratings generated profit
Average Return
+6.76%
reiterated a buy rating 3 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +6.76% per trade.
2 Years
xxx
Success Rate
20/28 ratings generated profit
Average Return
+9.67%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +9.67% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NBIX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
17
19
19
10
2
Buy
22
25
24
52
39
Hold
9
6
5
6
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
48
50
48
68
45
Each month's total comprises the sum of three months' worth of ratings.
NBIX Financial Forecast
NBIX Stock Forecast FAQ
What is NBIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurocrine’s 12-month average price target is 165.83.
What is NBIX’s upside potential, based on the analysts’ average price target?
Neurocrine has 25.99% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NBIX a Buy, Sell or Hold?
Neurocrine has a consensus rating of Strong Buy which is based on 22 buy ratings, 3 hold ratings and 0 sell ratings.
What is Neurocrine’s price target?
The average price target for Neurocrine is 165.83. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $124.00. The average price target represents 25.99% Increase from the current price of $131.62.
The highest analyst price target is $200.00 ,the lowest forecast is $124.00. The average price target represents 25.99% Increase from the current price of $131.62.
What do analysts say about Neurocrine?
Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
How can I buy shares of NBIX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.